Life Sciences Properties

Specialized lab space in cluster markets exposed to biotech risk

Life sciences properties are lab and R&D buildings with specialized infrastructure such as enhanced ventilation, backup power, and vibration control, concentrated in a handful of research cluster markets where tenant credit risk is elevated by many tenants being early-stage, pre-revenue biotech companies.

What Sets Lab and R&D Space Apart

Life sciences buildings require substantially more specialized infrastructure than standard office space, including enhanced air exchange and filtration rates, backup generator power, vibration control for sensitive equipment, reinforced floor loading, and specialized plumbing and gas lines. Space is generally categorized as wet lab (requiring water, gas, and chemical infrastructure for hands-on experimentation) or dry lab/office (computational or administrative work), and most buildings contain some mix of both.

Why Life Sciences Real Estate Clusters

Life sciences activity concentrates heavily in a small number of cluster markets — most notably Greater Boston/Cambridge, the San Francisco Bay Area, and San Diego — where proximity to leading research universities, deep scientific talent pools, and concentrated venture capital create self-reinforcing advantages. Because relocating a lab is disruptive and talent is difficult to replace elsewhere, tenants strongly prefer to stay within an established cluster even as rents rise.

Tenant Credit Risk from Early-Stage Biotech

A significant share of life sciences tenants are early-stage, pre-revenue companies funded by venture capital, grants, or partnership payments rather than product sales, meaning their ability to pay rent depends on continued fundraising success or clinical trial progress rather than steady operating income. Landlords commonly mitigate this by requiring larger security deposits or letters of credit and by closely tracking a tenant's funding stage and cash runway.

Underwriting and Conversion Considerations

Because lab build-outs are expensive and highly specialized, underwriters pay close attention to tenant improvement costs, the building's flexibility for re-tenanting if a lab tenant vacates, and the submarket's supply pipeline, since lab construction often surges during biotech funding booms and can lead to oversupply when funding tightens. A strong life sciences underwrite weighs both the durability of the cluster market and the credit quality and funding stability of the specific tenant roster.

Typical Tenants

  • Biotechnology and pharmaceutical companies
  • Academic and research institute spinouts
  • Contract research organizations (CROs)
  • Venture-backed early-stage life sciences startups

Key Underwriting Metrics

  • Tenant funding stage and cash runway (months of operating capital)
  • Weighted average lease term
  • Tenant improvement allowance per square foot
  • Mix of wet lab versus dry lab/office space
  • Security deposit or letter-of-credit coverage
  • Submarket lab vacancy and new supply pipeline

Major Risks

  • Tenant credit risk from pre-revenue, early-stage companies
  • High tenant improvement and re-tenanting costs if a lab tenant vacates
  • Cluster-market concentration and cyclical biotech funding swings
  • Limited alternative uses for highly specialized lab infrastructure
  • Regulatory and permitting complexity for lab operations

Typical Lender Fit

  • Banks and life insurance companies for stabilized, credit-tenant assets in established clusters
  • Debt funds and bridge lenders for lab conversions or spec lab construction
  • Life insurance companies favor long-leased large pharma/biotech credits
  • Construction lenders for ground-up lab development in core clusters

How It Makes Money

  • Base rent, often triple-net, on lab and office space
  • Tenant reimbursements for specialized utilities and systems
  • Premium rents versus standard office due to build-out cost and scarcity
  • Renewal and expansion income as successful tenants scale within the cluster

Lab Space Build-Out Classes

ClassDescriptionTypical Use
Wet labFull plumbing, gas, ventilation, and chemical infrastructureHands-on experimentation, biology/chemistry research
Dry lab / flexComputational or bench work with limited wet infrastructureData analysis, device development, light R&D
Shell/warm spaceBase building systems installed, lab fit-out not yet builtSpeculative space awaiting tenant-specific build-out
GMP manufacturing suiteHighly controlled environment meeting manufacturing standardsClinical or commercial-stage drug production

Underwrite the Tenant's Runway, Not Just the Lease Term

A long lease term is only as reliable as the tenant's ability to keep paying rent. For early-stage biotech tenants, track funding stage, recent capital raises, and estimated cash runway alongside the lease itself, since a strong lease with a tenant that runs out of funding still results in vacancy and costly re-tenanting.

Module Check

Question 1 of 1quick mode

Which factor most distinguishes life sciences lab space from standard office space?

Test Me on the Above

Check what you actually retained from Life Sciences Properties. Pick a mode:

Frequently Asked Questions

Why are life sciences properties concentrated in just a few cities?

Life sciences real estate clusters around research universities, talent pools, venture capital, and existing lab infrastructure, and these self-reinforcing advantages make a small number of established markets, such as Greater Boston, the San Francisco Bay Area, and San Diego, far more attractive than most other locations.

Why is tenant credit risk higher in life sciences buildings than in typical office buildings?

Many life sciences tenants are early-stage, pre-revenue biotechnology companies whose income depends on venture capital funding rounds or clinical trial milestones rather than product sales, making their ability to pay rent through a full lease term less certain than a typical established corporate office tenant.